Results 111 to 120 of about 957 (170)

Carbapenem-resistant <i>Acinetobacter baumannii</i> in resource-limited ICUs: when 'recommended therapy' is not realistically deliverable. [PDF]

JAC Antimicrob Resist
Saquib Alam M, Khatoon N.
europepmc   +1 more source

When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections? [PDF]

JAC Antimicrob Resist
Assimakopoulos SF, Ioannou S, Rodriguez-Bano J, Marangos M, Daikos GL.   +4 more
europepmc   +1 more source

Case Report: Early documented infected pancreatic necrosis due to carbapenem-resistant <i>Acinetobacter baumannii</i> and concurrent <i>Enterococcus faecium</i> bacteremia: a salvage regimen with sulbactam-durlobactam and tigecycline. [PDF]

Front Med (Lausanne)
Li M, Fu Y, Chen Y, Yu Y.
europepmc   +1 more source

Draft genome sequence of a KPC-2-producing, meropenem-durlobactam non-susceptible <i>Klebsiella pneumoniae</i> ST11-KL64 clinical isolate. [PDF]

Microbiol Resour Announc
Wen H, Feng Y, Zong Z.
europepmc   +1 more source

Disarming carbapenemase-producing <i>Acinetobacter baumannii</i>: high potency of the novel therapeutic combination of meropenem and the innovative diazabicyclooctane β-lactamase inhibitor pilabactam (formerly ANT3310). [PDF]

Antimicrob Agents Chemother
Rodríguez-Pallares S, Outeda-García M, Lence E, Rodríguez-Coello A, González-Pinto L, Guijarro-Sánchez P, Báez-Barroso GA, Blanco-Martín T, Vázquez-Ucha JC, Llanos A, Sannio F, Docquier J-D, Morrisey I, Hawser S, Zalacain M, Lemonnier M, González-Bello C, Bou G, Beceiro A, Arca-Suárez J.   +19 more
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source

Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA. [PDF]

Lancet Infect Dis
Ulloa ER, Jaffurs D, Tran MT, Lin C, Tran H, Chan D, Nael A, Nigwekar SU, Nikolich MP, Van Tyne D.   +9 more
europepmc   +1 more source

Clinico-Microbiological Profile of Carbapenem-Resistant Acinetobacter baumannii Isolates From Intensive Care Unit Patients and In Vitro Activity of Sulbactam-Durlobactam: A Cross-Sectional Study From Eastern India. [PDF]

Cureus
Susanna A, Singh N, Verma G, Mohapatra I, Pradhan S, Panda SS, Prince B, Pattnaik D, Mishra PP.   +8 more
europepmc   +1 more source

Turning the Tide Against Carbapenem-resistant Acinetobacter baumannii : Advancing Care With Sulbactam–Durlobactam

Open Forum Infectious Diseases
Michael Satlin, Ryan K Shields, Antoni Torres, Glenn Tillotson   +3 more
openaire   +2 more sources

Successful treatment of carbapenem-resistant <i>Acinetobacter baumannii</i> and Enterobacterales coinfection with sulbactam-durlobactam combined with aztreonam: a case report. [PDF]

AME Case Rep
Yang S, Cheng Z, Liu Y, Ni L, Wei C.
europepmc   +1 more source